Neovascular Age-Related Macular Degeneration (nAMD) – Epidemiology Insights and Disease Burden Report – 2020 To 2040
- Published Date : November 10, 2025
- Updated On : June 25, 2026
- Pages : 52
Neovascular Age-Related Macular Degeneration (nAMD) Epidemiology Insights and Disease Burden
Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Neovascular Age-Related Macular Degeneration (nAMD) Overview
Neovascular age-related macular degeneration (nAMD) is an advanced, exudative retinal condition characterized by choroidal neovascularization sprouting into the subretinal space. Driven by VEGF upregulation, these leaky vessels cause macular fluid accumulation, leading to rapid central vision loss. While diagnosis relies on clinic-based OCT and fluorescein angiography, active surveillance has shifted to include SCANLY Home OCT, a patient-operated, AI-driven device providing early detection of subclinical fluid recurrence between visits. Frontline management centers on proactive treat-and-extend intravitreal anti-VEGF protocols. To reduce treatment burden, frontline regimens deploy dual-action faricimab (targeting VEGF-A/Ang-2) and high-dose aflibercept 8mg to safely extend maintenance dosing to 16 weeks. Crucially, the long-term paradigm is moving toward sustained-expression platforms; late-stage clinical programs are anchored by advanced intravitreal gene therapies like 4D-150 and ixoberogene soroparvovec (Ixo-vec), which deliver endogenous anti-VEGF production to reduce injection frequency by up to 90%. Compliance tracking remains critical.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
Neovascular Age-Related Macular Degeneration (nAMD) Epidemiology Insights and Disease Burden
Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Neovascular Age-Related Macular Degeneration (nAMD) Overview
Neovascular age-related macular degeneration (nAMD) is an advanced, exudative retinal condition characterized by choroidal neovascularization sprouting into the subretinal space. Driven by VEGF upregulation, these leaky vessels cause macular fluid accumulation, leading to rapid central vision loss. While diagnosis relies on clinic-based OCT and fluorescein angiography, active surveillance has shifted to include SCANLY Home OCT, a patient-operated, AI-driven device providing early detection of subclinical fluid recurrence between visits. Frontline management centers on proactive treat-and-extend intravitreal anti-VEGF protocols. To reduce treatment burden, frontline regimens deploy dual-action faricimab (targeting VEGF-A/Ang-2) and high-dose aflibercept 8mg to safely extend maintenance dosing to 16 weeks. Crucially, the long-term paradigm is moving toward sustained-expression platforms; late-stage clinical programs are anchored by advanced intravitreal gene therapies like 4D-150 and ixoberogene soroparvovec (Ixo-vec), which deliver endogenous anti-VEGF production to reduce injection frequency by up to 90%. Compliance tracking remains critical.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)